Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

Abstract

Aim:The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational retrospective study was conducted on 129 consecutive patients with compensated cirrhosis treated in 2015, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensations. Results: The median follow-up time was 16 months. Most patients were males (73%), the mean age was 58.1 years and the most frequent genotype was 1b (52.2%). All participants were Child-Pugh A class at the start of the treatment and the median model for end-stage liver disease (MELD) score was 7. Four patients (4.4%) suffered a decompensation: three episodes of ascites and one acute on chronic liver failure. The incidence of de novo hepatocellular carcinoma during the follow-up was 3.6%. Seven patients (7.8%) improved MELD score more than one point and in 11 patients (12.2%) it worsened more than one point. There was a significant improvement in the mean platelets count [P < 0.001, 95% confidence interval (CI) : -26,360, -12,096] and in the mean albumin levels (P < 0.001, 95% CI: -322, -130) after treatment. Conclusion: Direct-acting antiviral treatment is not associated in the short term with a decrease in the development of hepatic decompensation or hepatocellular carcinoma compared to what it was reported for untreated compensated cirrhotic patients. There is an improvement in pre and post-treatment platelet counts and albumin levels showing a probable improvement of the hepatic function. Key words:Direct-acting antiviral therapy, compensated cirrhosis, hepatocellular carcinoma, clinical decompensation ABSTRACTArticle history:

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

“…As such, caution should be exercised when comparing safety outcomes reported in clinical trial and real‐world data sets. Results are consistent with previously reported real‐world G/P data, which showed low rates of severe AEs and AEs of special interest 36,37 …”

“…This is an expected finding, as safety is often under- G/P data, which showed low rates of severe AEs and AEs of special interest. 36,37 In both cohorts, normalization of laboratory parameters was observed across the subgroups. Platelet normalization was rare; however, as low platelet count is a consequence of portal hypertension, platelet count rarely normalizes, even in patients who undergo a liver transplant as the spleen remains large.…”

“…Results are consistent with previously reported real‐world G/P data, which showed low rates of severe AEs and AEs of special interest. 36 , 37 …”

<p>Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed</p>

“…14 We have found that there is a statistically significant improvement in platelet counts and in albumin levels liked Berge study results . 26 Patients who have achieved SVR have shown a significant reduction in the frequency of hepatic encephalopathy episodes, improvement in the management of ascites.…”

New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin

“…As they cause a rapid decrease in HCV RNA levels leading to a fast decline in natural killer cells (NK) activity. 8 The study aimed to examine new-onset or relapse of HCC in patients receiving Sofosbuvir and Daclatasvir both with and without Ribavirin.…”